Tissue Regenix Group Stock Revenue
| TRX Stock | 58.50 1.50 2.50% |
Tissue Regenix Group fundamentals help investors to digest information that contributes to Tissue Regenix's financial success or failures. It also enables traders to predict the movement of Tissue Stock. The fundamental analysis module provides a way to measure Tissue Regenix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tissue Regenix stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 33.9 M | 35.6 M |
Tissue | Revenue |
Tissue Regenix Group Company Revenue Analysis
Tissue Regenix's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Tissue Regenix Revenue | 29.49 M |
Most of Tissue Regenix's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tissue Regenix Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Tissue
Projected quarterly revenue analysis of Tissue Regenix Group provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Tissue Regenix match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Tissue Regenix's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Tissue Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Tissue Regenix Group reported 29.49 M of revenue. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The revenue for all United Kingdom stocks is notably lower than that of the firm.
Tissue Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tissue Regenix's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tissue Regenix could also be used in its relative valuation, which is a method of valuing Tissue Regenix by comparing valuation metrics of similar companies.Tissue Regenix is currently under evaluation in revenue category among its peers.
Tissue Fundamentals
| Return On Equity | -0.0331 | ||||
| Return On Asset | 0.005 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 47.34 M | ||||
| Shares Outstanding | 71.23 M | ||||
| Shares Owned By Insiders | 51.91 % | ||||
| Shares Owned By Institutions | 34.85 % | ||||
| Price To Book | 1.72 X | ||||
| Price To Sales | 1.31 X | ||||
| Revenue | 29.49 M | ||||
| Gross Profit | 11.26 M | ||||
| EBITDA | 446 K | ||||
| Net Income | (1.67 M) | ||||
| Total Debt | 9.39 M | ||||
| Book Value Per Share | 0.43 X | ||||
| Cash Flow From Operations | 1.04 M | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 120.0 | ||||
| Number Of Employees | 82 | ||||
| Beta | 1.58 | ||||
| Market Capitalization | 41.67 M | ||||
| Total Asset | 43.24 M | ||||
| Retained Earnings | (123.76 M) | ||||
| Working Capital | 14.36 M | ||||
| Net Asset | 43.24 M |
About Tissue Regenix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tissue Regenix Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tissue Regenix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tissue Regenix Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Other Information on Investing in Tissue Stock
Tissue Regenix financial ratios help investors to determine whether Tissue Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Tissue with respect to the benefits of owning Tissue Regenix security.